JP2019511536A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511536A5
JP2019511536A5 JP2018553923A JP2018553923A JP2019511536A5 JP 2019511536 A5 JP2019511536 A5 JP 2019511536A5 JP 2018553923 A JP2018553923 A JP 2018553923A JP 2018553923 A JP2018553923 A JP 2018553923A JP 2019511536 A5 JP2019511536 A5 JP 2019511536A5
Authority
JP
Japan
Prior art keywords
medicament
subject
epidural space
hypertension
thoracic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018553923A
Other languages
English (en)
Japanese (ja)
Other versions
JP6980694B2 (ja
JP2019511536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/027480 external-priority patent/WO2017180907A1/en
Publication of JP2019511536A publication Critical patent/JP2019511536A/ja
Publication of JP2019511536A5 publication Critical patent/JP2019511536A5/ja
Priority to JP2021170184A priority Critical patent/JP7341203B2/ja
Application granted granted Critical
Publication of JP6980694B2 publication Critical patent/JP6980694B2/ja
Priority to JP2023138999A priority patent/JP2023155365A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018553923A 2016-04-13 2017-04-13 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法 Active JP6980694B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021170184A JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2023138999A JP2023155365A (ja) 2016-04-13 2023-08-29 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322079P 2016-04-13 2016-04-13
US62/322,079 2016-04-13
PCT/US2017/027480 WO2017180907A1 (en) 2016-04-13 2017-04-13 Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021170184A Division JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2019511536A JP2019511536A (ja) 2019-04-25
JP2019511536A5 true JP2019511536A5 (https=) 2020-05-14
JP6980694B2 JP6980694B2 (ja) 2021-12-15

Family

ID=60039929

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553923A Active JP6980694B2 (ja) 2016-04-13 2017-04-13 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2021170184A Active JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2023138999A Pending JP2023155365A (ja) 2016-04-13 2023-08-29 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021170184A Active JP7341203B2 (ja) 2016-04-13 2021-10-18 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法
JP2023138999A Pending JP2023155365A (ja) 2016-04-13 2023-08-29 投与のための方法およびレシニフェラトキシンで心血管疾患を治療する方法

Country Status (9)

Country Link
US (3) US20170296506A1 (https=)
EP (1) EP3442523A4 (https=)
JP (3) JP6980694B2 (https=)
KR (2) KR102395342B1 (https=)
CN (2) CN120114438A (https=)
AU (1) AU2017248665B2 (https=)
CA (1) CA3020815A1 (https=)
IL (2) IL298314B2 (https=)
WO (1) WO2017180907A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490745A (zh) 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
EP3914595A4 (en) 2019-01-22 2022-11-09 Sorrento Therapeutics, Inc. METHOD OF TREATMENT OF OSTEOARTHRITIS PAIN BY ADMINISTRATION OF RESINIFERATOXIN
CA3188689A1 (en) * 2020-08-11 2022-02-17 Alexis G. Nahama Treating pulmonary inflammatory disease by neural ablation
CA3219312A1 (en) * 2021-05-18 2022-11-24 Alexis Nahama Presurgical perineural administration of resiniferatoxin for reduction of post-operative pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
WO2007017764A2 (en) * 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
US20100158973A1 (en) * 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
CN101522181A (zh) * 2006-10-04 2009-09-02 纽若科伊公司 诱导低体温药物在治疗局部缺血的应用
CN101951937A (zh) * 2007-12-21 2011-01-19 赫尔辛医疗股份公司 使用伊帕瑞林刺激胃肠系统动力的方法
WO2012045587A1 (en) * 2010-10-06 2012-04-12 Celltrend Gmbh A new method for diagnosing hypertension as well as cardiomyopathies
MY172557A (en) * 2013-09-17 2019-12-02 Vectus Biosystems Ltd Compositions for the treatment of hypertension and/or fibrosis
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin

Similar Documents

Publication Publication Date Title
Yin et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation
Gheorghiade et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes
JP2019511536A5 (https=)
Ichinose et al. Modulation of cardiac output alters the mechanisms of the muscle metaboreflex pressor response
Davidson et al. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index≥ 27 kg/m2
EP2988750B2 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
JP2014511365A5 (https=)
RU2015142255A (ru) Фармацевтическое комбинированное лекарственное средство
Farsang Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
JP6509729B2 (ja) 慢性腎臓病の進行抑制又は改善剤
Frank Peacock IV et al. Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis
Chhabra et al. Orthostatic hypertension: recognizing an underappreciated clinical condition
KR20220062667A (ko) 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법
Upadhya et al. Heart failure prevention in older patients using intensive blood pressure reduction: potential role of diuretics
Ramchandra et al. Responses of cardiac sympathetic nerve activity to changes in circulating volume differ in normal and heart failure sheep
JP2008534621A5 (https=)
EP2925128A1 (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
Aronow Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly
Sanford et al. Acute takotsubo cardiomyopathy during elective hernia repair in a patient with previously resected pheochromocytoma
JP6684264B2 (ja) 心不全の予防又は治療のための医薬
Tolentino et al. 1173: Successful use of lipid infusion and plasmapheresis after massive bupropion overdose
CN101879165A (zh) 一种新型抗高血压药物复方制剂
Bhargava et al. Perioperative management of a patient with left ventricular dysfunction and anomalous coronary arteries
Kalus Pharmacotherapeutic decision-making for patients with atrial fibrillation
Collins et al. True isolated right ventricular infarction with tombstone anterior ST elevation